Alzheimer’s disease - AEN-100

Adeona is preparing a larger clinical study protocol to evaluate patients diagnosed with mild to moderate Alzheimer’s disease who are age 70 and over. It is anticipated that the clinical study will enroll over 100 patients and that the evaluation period will be at least 12 months. The intention is to develop the Company’s proprietary zinc-based tablet as a drug (in parallel with making reaZin available as a prescription medical food) and to conduct this new clinical study under an Investigational New Drug  application to be filed with the Food & Drug Administration. This study is intended to evaluate the safety and efficacy of the following proprietary drug candidate:

• AEN-100, a once-daily, gastroretentive, sustained-release oral tablet formulation of zinc acetate